About Om Pharmaceuticals Limited
Data last updated: 18 February 2026
Om Pharmaceuticals Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in ayurvedic products and services, a part of the broader healthcare sector. Incorporated on 08 November 1994, the company has been in operation for over 32 years.
Registered with ROC Mumbai under CIN U24230MH1994PLC082689.
Capital: an authorised share capital of ₹20 Lakh and a paid-up capital of ₹9.2 Lakh. It is led by directors including Chetan Doshi Mansukhlal and Vivek Gul Asrani.
Last AGM: 26 September 2025. Financial statements filed for year ended 31 March 2025. Office: 202 Vishwa Nanak Apartments Gurunanak Wadi Chakala Andheri (East), Mumbai, Maharashtra, India – 400099.
As per the financials filed for FY 2025, the company reported a revenue of ₹83.53 Cr, a growth of 6% compared to the previous year.
The company is associated with 2 brands - Om Pharmaceutical Industries, Shree Dhootapapeshwar. As per MCA filings, the company has open charges of ₹40 Lakh and satisfied charges of ₹8.95 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sdlindia.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered Address202 Vishwa Nanak Apartments Gurunanak Wadi Chakala Andheri (East), Mumbai, Maharashtra, India – 400099
-
IndustryHealthcare, Ayurvedic Products & Services
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Associated Brands with Om Pharmaceuticals Limited
Om Pharmaceuticals Limited operates two associated brands: Om Pharmaceutical Industries and Shree Dhootapapeshwar. These brands represent Om Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufactures and supplies active pharmaceutical ingredients and intermediates with FDA-approved facilities. | ompharmaceutical.com | |
| Ayurvedic medicines | sdlindia.com |
Competitors & Alternatives of Om Pharmaceuticals Limited
Brands and companies operating in the same space as Om Pharmaceuticals Limited include Laurus Labs, Symbiotec, Beijing Biostar Technologies and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Laurus Labs
|
Pharmaceutical and biotechnology company | Hyderabad, India, India | 2005 |
Symbiotec
|
Non-sterile steroid hormone-based APIs and intermediates are manufactured. | Indore, India, India | 2002 |
Beijing Biostar Technologies
|
APIs, intermediates, and biochemical reagents are developed and manufactured. | Beijing, China, China | 2002 |
Sterling Pharma Solutions
|
Contract development, manufacturing, and analytical services for APIs are offered. | Dudley, United Kingdom, United Kingdom | 2016 |
Provepharm Life Solutions
|
APIs and drug products are developed and valorized in pharmaceuticals. | Marseille, France, France | 1998 |
Hikal
|
APIs and intermediates are produced via custom synthesis and research. | Mumbai, India, India | 1988 |
Snapdragon Chemistry
|
Drug discovery and development service provider | Cambridge, United States, United States | 2014 |
SeQuent
|
APIs are developed and manufactured for therapeutic areas. | Bengaluru, India, India | 2002 |
Jubilant Pharma
|
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company. | Noida, India, India | 1978 |
Business Activity of Om Pharmaceuticals Limited
Om Pharmaceuticals Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Om Pharmaceuticals Limited
Om Pharmaceuticals Limited is audited by KALYANIWALLA & MISTRY LLP for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| KALYANIWALLA & MISTRY LLP | blur-value | blur-value | blur-value |
Board of Directors of Om Pharmaceuticals Limited
Om Pharmaceuticals Limited is currently managed by 4 directors, with 5 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Chetan Doshi Mansukhlal
Also directs:
U.D. Industries Private Limited
|
Director | 27 Dec 2019 | 6 Years 6 Months | Current |
|
Vivek Gul Asrani
Also directs:
Grp Limited, Cartrade Tech Limited, Indo-Italian Furniture Company Private Limited and 3 more
|
Director | 01 Apr 2005 | 21 Years 3 Months | Current |
| Vishal Narindernath Mehra | Director | 20 Jul 2012 | 13 Years 11 Months | Current |
| Pravin Gangadhar Sonawane | Director | 09 Sep 2024 | 1 Years 10 Months | Current |
Financials of Om Pharmaceuticals Limited FY 2025 filings available
Om Pharmaceuticals Limited reported revenue of ₹83.53 Cr (up 6% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Shareholding Pattern of Om Pharmaceuticals Limited
As of FY 2023, Om Pharmaceuticals Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.
| Year | 2025 |
|---|---|
| Promoters | 33.19% |
| DII | 23.22% |
| FII | 18.28% |
| Public | 22.89% |
| Others | 2.42% |
Charges & Borrowings of Om Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Sep 2024 | Others | ₹40 Lakh | Open |
| 10 Oct 2013 | Bank of Maharashtra | ₹85 Lakh | Satisfied |
| 03 Nov 2011 | Bank of Maharashtra | ₹1.1 Cr | Satisfied |
| 08 Jul 2010 | Bank of Maharashtra | ₹1.35 Cr | Satisfied |
| 03 Apr 2007 | Others | ₹3.2 Cr | Satisfied |
Total charge records: 8 View all charges
Employees and EPFO Compliance at Om Pharmaceuticals Limited
View historical data on people associated with Om Pharmaceuticals Limited, including employment history and EPFO contributions.
Employee Count & EPFO Data of Om Pharmaceuticals Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Om Pharmaceuticals Limited
GSTIN & GST Filing Data of Om Pharmaceuticals Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Om Pharmaceuticals Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Om Pharmaceuticals Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Om Pharmaceuticals Limited
MSME Payment Delays by Om Pharmaceuticals Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Om Pharmaceuticals Limited
Subsidiaries & Group Companies of Om Pharmaceuticals Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Om Pharmaceuticals Limited with ownership details.
MCA Filings & Documents of Om Pharmaceuticals Limited
MCA Filings & Documents of Om Pharmaceuticals Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Om Pharmaceuticals Limited
Frequently Asked Questions about Om Pharmaceuticals Limited
Om Pharmaceuticals Limited is an active public limited company in the healthcare sector based in Mumbai, Maharashtra, India. It was incorporated on 08 November 1994 (32+ years old) and is registered under CIN U24230MH1994PLC082689.
Om Pharmaceuticals Limited reported revenue of ₹83.53 Cr for FY 2025 (up 6.00% YoY).
The current directors of Om Pharmaceuticals Limited are:
The primary industry of Om Pharmaceuticals Limited is healthcare. The company specifically operates in ayurvedic products and services. The company is currently active in this sector.
Om Pharmaceuticals Limited can be reached at the registered office: 202 Vishwa Nanak Apartments Gurunanak Wadi Chakala Andheri East, Mumbai, Maharashtra, India – 400099, or through the website sdlindia.com.
The authorised capital is ₹20 Lakh, and the paid-up capital is ₹9.2 Lakh.